Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 5.81M +1.2% |
| Revenue (ttm) | n/a |
| Net Income | -7.77M |
| EPS | -8.22 |
| Shares Out | 2.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,517 |
| Open | 2.610 |
| Previous Close | 2.600 |
| Day's Range | 2.530 - 2.890 |
| 52-Week Range | 1.310 - 18.900 |
| Beta | 1.46 |
| Analysts | Buy |
| Price Target | 7.00 (+158.3%) |
| Earnings Date | Aug 12, 2026 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ADIL stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 158.30% from the latest price.
News
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Director...
Adial Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $6 price target The firm says the company’s newly acquired lead program is AT177 is a proprietary…
Adial Pharmaceuticals Press release: M&A announcement
Adial Pharmaceuticals issued a press release on June 11, 2026, disclosing material business information to investors.
Adial Pharmaceuticals announces acquisition of Azora Therapeutics
Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a pr...
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mi...
Adial Pharmaceuticals Slides: Corporate presentation
Adial Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...
Adial Pharmaceuticals Quarterly report: Q1 2026
Adial Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
Adial Pharmaceuticals Earnings release: Q1 2026
Adial Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Adial Pharmaceuticals files AD04 utility application with USPTO
Adial Pharmaceuticals (ADIL) announced the filing of a new U.S. utility application with the United States Patent and Trade Office, or USPTO, directed to AD04, the company’s lead investigational genet...
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility...
Adial submits AD04 product application for FDA CNPV pilot program
Adial Pharmaceuticals (ADIL) announced the submission of the AD04 product application for consideration of the FDA Commissioner’s National Priority Voucher Pilot Program. Announced in 2025, the CNPV p...
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatme...
Adial Pharmaceuticals completes AD04 demonstration batch production
Adial Pharmaceuticals (ADIL) announced completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for th...
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product produc...
Adial Pharmaceuticals expects cash to fund operations into 2H of 2026
Cash and cash equivalents were $5.9 million as of December 31, 2025, compared to $3.8 million as of December 31, 2024. The Company believes that its existing cash and cash…
Adial Pharmaceuticals Annual report: Q4 2025
Adial Pharmaceuticals has published its Q4 2025 annual report on March 5, 2026.
Adial Pharmaceuticals Earnings release: Q4 2025
Adial Pharmaceuticals released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
Adial Pharmaceuticals (ADIL) announced it has entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership covering the commercialization of AD04 in ...
Adial Pharmaceuticals Slides: Investor presentation
Adial Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Adial Pharmaceuticals regains compliance with Nasdaq listing requirement
Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq…
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3
Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden
Adial Pharmaceuticals (ADIL) highlighted recent U.S. Food and Drug Administration, FDA, policy direction described by FDA Commissioner Martin Makary, M.D., M.P.H., and Vinay Prasad, M.D., M.P.H., in a...
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Subm...
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
Maxim lowered the firm’s price target on Adial Pharmaceuticals (ADIL) to $8 from $37.50 and keeps a Buy rating on the shares. The firm remains positive on the stock based…